Sevket Balta1, Turgay Celik2, Cengiz Ozturk2, M Gungor Kaya3, Mustafa Aparci2, A Osman Yildirim2, Mustafa Demir2, Selim Kilic4, İbrahim Aydin5, Atila Iyisoy2. 1. Gulhane Military Medical Academy, School of Medicine, Dept. of Cardiology, Etlik, Ankara, Turkey. Electronic address: drsevketb@gmail.com. 2. Gulhane Military Medical Academy, School of Medicine, Dept. of Cardiology, Etlik, Ankara, Turkey. 3. Erciyes University, School of Medicine, Dept. of Cardiology, Kayseri, Turkey. 4. Gulhane Military Medical Academy, School of Medicine, Dept. of Epidemiology, Etlik, Ankara, Turkey. 5. Gulhane Military Medical Academy, School of Medicine, Dept. of Clinical Biochemistry, Etlik, Ankara, Turkey.
Abstract
BACKGROUND: No-reflow phenomenon is a prognostic value in ST-segment elevation myocardial infarction (STEMI). Monocyte to high density lipoprotein ratio (MHR) has recently emerged as a marker of inflammation and oxidative stress in the cardiovascular disease. PURPOSE: In this study, we aimed to investigate the relation between MHR and no-reflow phenomenon in patients with STEMI undergoing primary percutaneous coronary intervention (pPCI). MATERIAL AND METHODS: A total of 600 patients with STEMI (470 men; mean age, 62 ± 12 years) admitted within 12 hours from symptom onset were included into this study. Patients were classified into 2 groups based on postintervention Thrombolysis in Myocardial Infarction (TIMI) flow grade: no-reflow-TIMI flow grade 0, 1, or 2 (group 1); angiographic success-TIMI flow grade 3 (group 2). RESULTS: According to admission whole-blood cell count results, the patients in the no-reflow group had significantly higher monocyte count and MHR values when compared with those of the reflow patients. After multivariate backward logistic regression, MHR remained independent predictors of no reflow after pPCI. Adjusted odds ratios were calculated as 1.09 for MHR (P< .001; confidence interval [CI], 1.07-1.12). Receiver operating characteristic curve analysis suggested that the optimum MHR level cutoff point for patients with no-reflow was 22.5, with a sensitivity and specificity of 70.2% and 73.3%, respectively (area under curve, 0.768; 95% CI, 0.725-0.811). CONCLUSION: In conclusion, MHR levels are one of the independent predictors of no reflow in patients with STEMI after pPCI.
BACKGROUND: No-reflow phenomenon is a prognostic value in ST-segment elevation myocardial infarction (STEMI). Monocyte to high density lipoprotein ratio (MHR) has recently emerged as a marker of inflammation and oxidative stress in the cardiovascular disease. PURPOSE: In this study, we aimed to investigate the relation between MHR and no-reflow phenomenon in patients with STEMI undergoing primary percutaneous coronary intervention (pPCI). MATERIAL AND METHODS: A total of 600 patients with STEMI (470 men; mean age, 62 ± 12 years) admitted within 12 hours from symptom onset were included into this study. Patients were classified into 2 groups based on postintervention Thrombolysis in Myocardial Infarction (TIMI) flow grade: no-reflow-TIMI flow grade 0, 1, or 2 (group 1); angiographic success-TIMI flow grade 3 (group 2). RESULTS: According to admission whole-blood cell count results, the patients in the no-reflow group had significantly higher monocyte count and MHR values when compared with those of the reflow patients. After multivariate backward logistic regression, MHR remained independent predictors of no reflow after pPCI. Adjusted odds ratios were calculated as 1.09 for MHR (P< .001; confidence interval [CI], 1.07-1.12). Receiver operating characteristic curve analysis suggested that the optimum MHR level cutoff point for patients with no-reflow was 22.5, with a sensitivity and specificity of 70.2% and 73.3%, respectively (area under curve, 0.768; 95% CI, 0.725-0.811). CONCLUSION: In conclusion, MHR levels are one of the independent predictors of no reflow in patients with STEMI after pPCI.
Authors: Muhammed Süleymanoğlu; İbrahim Rencüzoğulları; Yavuz Karabağ; Metin Çağdaş; Mahmut Yesin; Ayça Gümüşdağ; Murat Çap; Murat Gök; İbrahim Yıldız Journal: Int J Cardiovasc Imaging Date: 2020-01-09 Impact factor: 2.357
Authors: Aydın Rodi Tosu; Muhsin Kalyoncuoğlu; Halil İbrahim Biter; Sinem Çakal; Beytullah Çakal; Murat Selçuk; Tufan Çinar Journal: Arch Med Sci Atheroscler Dis Date: 2022-07-07
Authors: Mustafa Umut Somuncu; Tunahan Akgun; Mustafa Ozan Cakır; Ferit Akgul; Nail Guven Serbest; Huseyin Karakurt; Murat Can; Ali Riza Demir Journal: J Atheroscler Thromb Date: 2019-04-18 Impact factor: 4.928